Pfizer's 4Q net plunges on charges, sales decline

by Linda A. Johnson
In this Jan. 30, 2012 file photo, boxes of the drug Relpax, made by Pfizer, are displayed in Surfside, Fla. Pfizer reports quarterly results before the market open on Tuesday, Jan. 28, 2014. (AP Photo/Wilfredo Lee, File)

Drugmaker Pfizer said Tuesday that fourth-quarter profit plunged 59 percent because of discontinued operations, restructuring and other charges, and generic competition continuing to siphon off revenue from former blockbuster medicines.

Despite a 3 percent revenue decline caused by those pressures and unfavorable currency exchange rates, Pfizer easily topped Wall Street's modest expectations.

Pfizer's stock rose 59 cents, or 2 percent, to $30.25 in premarket trading.

The world's second-biggest drugmaker said was $2.57 billion, or 39 cents per share, down from $6.32 billion, or 85 cents per share, a year earlier.

Excluding one-time items, the maker of Viagra, arthritis Xeljanz and pneumonia vaccine Prevnar said net income would have been $3.69 billion, or 56 cents per share. That topped analyst expectations of 52 cents per share.

Revenue totaled $ 13.56 billion, down 2 percent. Analysts expected $13.36 billion.

Sales of primary care drugs fell 10 percent to $3.44 billion, mainly because of generic competition for Viagra in Europe and for the cholesterol fighter Lipitor.

Lipitor, the world's top-selling drug for nearly a decade until it got U.S. generic competition two years ago, now faces cheaper copycats in Europe and Australia as well. Those smaller revenues have been shifted to the company's established products unit, which saw sales edge up 2 percent to $2.42 billion.

Pfizer's specialty care division posted a 7 percent drop in sales to $3.4 billion, because of in foreign countries for schizophrenia treatment Geodon and blood pressure drug Revatio. Pfizer also received lower royalties from immune disorder drug Enbrel as a co-promotion deal for that winds down.

Consumer health care revenue edged up 1 percent to $943 million. The bright spot was Pfizer's fledgling cancer drug business, which posted a 26 percent jump to $468 million.

The New York-based drugmaker forecast 2014 profit of $1.57 to $1.72 per share, or $2.20 to $2.30 excluding one-time items.

"We enter 2014 with confidence in the competitive positioning of our commercial businesses, the prospects for our recently launched products and the strength of our research pipeline," CEO Ian Read said in a statement.

He noted Pfizer will be reporting on midstage research results this year for experimental drugs for advanced breast cancer, high cholesterol and, for Xeljanz, testing against another immune disorder, psoriasis.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Pfizer 3Q net falls due to generics, higher costs

Oct 29, 2013

Pfizer Inc.'s third-quarter profit dropped 19 percent as competition from generic drugs continued to cut sales, while lower operating expenses failed to offset higher taxes and charges.

Pfizer Q4 net jumps on sale of nutrition business

Jan 29, 2013

Pfizer Inc.'s fourth-quarter profit more than quadrupled, despite competition from generic drugs hurting sales of Lipitor and other medicines, because of a $4.8 billion gain from selling its nutrition business. ...

Merck 3Q net income falls on charges, lower sales

Oct 28, 2013

Merck & Co. said Monday that its third-quarter profit plunged 35 percent because of competition from generic drugs, lower sales of its top-selling medicine, and restructuring and acquisition charges. It still beat Wall Street's ...

Pfizer 2Q mixed, maintains 2013 outlook

Jul 30, 2013

Pfizer's second-quarter net income more than quadrupled, helped by the sale of its animal health business. The world's second-largest drugmaker beat Wall Street's earnings expectations, though revenue continued to decline ...

Pfizer, Teva reach deal to allow generic Viagra

Dec 17, 2013

Pfizer says it reached a settlement with Teva Pharmaceuticals that allows the generic drugmaker to launch a copycat version of its popular erectile dysfunction drug Viagra in 2017.

Recommended for you

British Lords hold ten-hour debate on assisted dying

Jul 19, 2014

Members of Britain's unelected House of Lords spent almost ten hours on Friday discussing whether to legalise assisted dying, in an often emotional debate putting the question back on the agenda, if not on the statute books.

AbbVie, Shire agree on $55B combination

Jul 18, 2014

The drugmaker AbbVie has reached a deal worth roughly $55 billion to combine with British counterpart Shire and become the latest U.S. company to seek an overseas haven from tax rates back home.

Safety problems at US germ labs acknowledged

Jul 16, 2014

(AP)—The director of the U.S. Centers for Disease Control and Prevention acknowledged Wednesday that systemic safety problems have for years plagued federal public health laboratories that handle dangerous ...

User comments